Related Experiment Videos
[Gene therapy for Parkinson's disease].
1Division of Neurology, Department of Medicine, Jichi Medical School.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 7, 2004
Summary
Gene therapy using adeno-associated viral (AAV) vectors shows promise for Parkinson's disease (PD). Delivering dopamine-synthesizing enzymes or neurotrophic factors can restore dopamine production and rescue neurons, offering a potential new treatment for PD.
Area of Science:
- Neuroscience
- Molecular Biology
- Gene Therapy
Context:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Current treatments manage symptoms but do not halt disease progression.
- Advances in gene transfer offer new therapeutic avenues.
Purpose:
- To evaluate the potential of gene therapy for Parkinson's disease.
- To assess the efficacy of adeno-associated viral (AAV) vectors for delivering therapeutic genes.
- To explore strategies for restoring dopamine production and protecting neurons in PD models.
Summary:
- High-titer recombinant adeno-associated viral (AAV) vectors enable gene therapy for Parkinson's disease.
- Efficient, long-term expression of dopamine (DA)-synthesizing enzymes in the striatum restored DA production and behavioral recovery in PD animal models.
- Sustained glial cell line-derived neurotrophic factor gene expression rescued nigral neurons and improved function in a rat PD model, even with delayed treatment.
- A clinical trial is investigating subthalamic transduction for inhibitory neurotransmitter production.
Impact:
- Gene therapy presents a feasible therapeutic option for Parkinson's disease.
- Restoring local dopamine production and protecting neurons are key strategies for PD treatment.
- This approach holds potential for halting or reversing neurodegeneration in Parkinson's disease.